MDM. V. Davydovskaya

M. V. Davydovskaya

*This is an algorithmically generated author record based on publicly available information.

M. V. Davydovskaya has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding the indications of cladribine tablets for multiple sclerosis: From early use in treatment-naive patients to the possibility of retreatment courses after 4 years of cladribine initiation therapy

    by E. V. Popova, N. V. Khachanova, M. V. Abroskina, M. V. Davydovskaya, E. P. Evdoshenko, M. V. Shumilina, D. S. Korobko, A. I. Nilov, M. V. Sutormin, Yu. V. Trinitatskiy, et al.

    Autoimmune disorders are common clinical conditions that result from an abnormal immune response to the body’s own structures. Most existing immunomodulatory drugs for multiple sclerosis (MS) therapy are capable of suppressing autoimmune reactions as long as they are used, but they do not target autoreactive immunological memory and cannot disable the underlying mechanisms to induce remission without therapy. Over the past decade, there has been an increased interest in highly effective immune reconstruction therapy (IRT), which can transiently or persistently provoke the immune system resetting. Cladribine (2-chloro-deoxyadenosine) in tablets belongs to the group of IRT drugs for relapsing multiple sclerosis (RMS), which therapy consists of two short courses of treatment during the 1st and 2nd year. Most patients achieve sustained efficacy with the use of cladribine, but a small proportion of patients may experience new disease activity that requires the treating physician to make a decision regarding a previously chosen treatment strategy. Since cladribine tablets were approved by the European Union, USA and Russia more than 5 years ago, the number of publications devoted to the analysis of real-world practice has been steadily increasing. The purpose of this publication is to present the results of Expert Council conducted in February 2026. The participants of the expert council developed further recommendations for the administration of the drug to therapeutically naive patients with relapsing-remitting MS, in secondary progressive MS with exacerbations, algorithms for managing patients with RMS with disease activity reactivation after the initial 2 courses of therapy with cladribine and subsequent follow-up, and discussed the profiles of patients in whom switching to cladribine tablets is considered as an option that reduces the risks of prolonged immunosuppression.

  • Open Access

    Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential

    by V. S. Krasnov, Ya. V. Vlasov, E. Р. Evdoshenko, D. S. Korobko, V. М. Lebedev, I. G. Lukashevich, A. I. Nilov, E. S. Novikova, E. V. Popova, K. V. Sapozhnikov, et al.

    Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory diseases of the central nervous system. B-lymphocytes play leading role in their pathogenesis in most cases. СD20 surface antigen is one of the B-lymphocytes makers. There is extensive world experience with chimeric monoclonal anti-CD20 antibody rituximab off-label using for NMOSD exacerbations prevention. It has been included in published international and Russian algorithms for NMOSD treatment along with other approved medications. Divozilimab is recombinant humanized anti-CD20 monoclonal antibody with a modified glycosylation pattern of Fc-fragment which is approved in Russian Federation for the treatment of multiple sclerosis, systemic scleroderma and also for NMOSD (September 2025). The publication is intended to present the results of the Russian Expert Councils work in September 2025 and February 2026. According to the analysis of publications on anti-CD20 NMOSD therapy, the 6-month results of divozilimab study BCD-132-6/AQUARELLE (NCT05730699) and data of additional subanalysis experts agreed the profiles of NMOSD patients for divozilimab therapy, time to full therapeutic effect and monitoring plan during treatment with divozilimab. Experts supplemented the algorithm for initial prescription and switching of medications for prevention of NMOSD attacks in patients with AQP4-IgG aged 18 years and older, agreed on the algorithm for the administration of medications for prevention of NMOSD attack in patients without AQP4-IgG aged 18 years and older, determined positions of divozilimab in both algorithms. According to experts opinion divozilimab appears as promising treatment option in NMOSD. Analysis of divozilimab effectiveness and safety long-term results in BCD-132-6/AQUARELLE study and real-world practice will be important steps toward clarifying and potentially extending patient profiles.

  • Open Access

    Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation

    by V. S. Krasnov, M. P. Abramova, M. A. Bakalova, A. I. Bezvodinskikh, R. Ts. Bembeeva, Z. S. Gasanova, E. P. Evdoshenko, N. V. Zhukovskaya, O. V. Zaplakhova, S. P. Ivanova, et al.

    Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.

  • Open Access

    Cladribine in tablets in real clinical practice: Results of treatment of 267 patients with multiple sclerosis in Moscow

    by E. V. Popova, V. B. Sosina, S. N. Sharanova, S. N. Zolotova, I. M. Shalabanova, N. V. Khachanova, M. V. Davydovskaia, L. Yu. Gorshkova, D. M. Fekhretdinova, N. F. Smirnova, et al.

    Introduction. Over the past 30 years, there has been a dramatic change in approaches to the treatment of multiple sclerosis (MS), due to the development of a large number of drugs with different mechanisms of action for the disease-modifying treatment (DMT) of MS.Aim. To form, based on the analysis of the obtained data, an optimal algorithm for the management of patients with MS receiving cladribine tablets in the conditions of real clinical practice.Materials and methods. A retrospective analysis of the data obtained on the background of therapy with cladribine in MS patients at the end of 2024 was conducted on the basis of the Moscow inter-district departments of MS. The data from outpatient records of MS patients treated with cladribine from 2021 to 2023 were used as research material. Data collection was carried out on the initial clinical and demographic characteristics of patients, as well as indicators of the effectiveness of therapy (average annual frequency of exacerbations, activity according to MRI data and progression according to the EDSS scale) and the presence of adverse reactions against the background of therapy with cladribine.Results. This publication presents the experience of using the drug cladribine in real clinical practice in 267 MS patients in Moscow in the period from 2021 to 2023. Patients who underwent two full annual courses of therapy showed a significant reduction in the mean annual frequency of exacerbations and brain MRI activity after the first year of therapy. There was also no significant increase in neurological deficits according to the EDSS scale. During the safety analysis, good tolerability of the drug was noted. The spectrum of adverse events and their frequency were comparable to the data of the instructions for medical use. Conclusion. Effective treatment of MS patients requires optimizing therapy, balancing benefits and risks, and long-term treatment planning from the moment of diagnosis. All these principles can be met with an understanding of the mechanism of action of the drugs and clear adherence to recommendations for monitoring the duration of washout periods when switching from one MS-modifying drug to another.


  • Open Access

    Administration of siponimod in real clinical practice in Russia

    by M. V. Davydovskaia, N. Sh. Arzumanyan, E. A. Dubchenko, V. B. Sosina, M. V. Shumilina, E. V. Krivomlina, L. Yu. Gorshkova, M. V. Sutormin, A. A. Sokolova, K. Z. Bakhtiyarova, et al.

    Introduction. The study was driven by the prevalence of secondary progressive multiple sclerosis (SPMS) in Russia and the lack of data on siponimod in the real clinical practice (RCP).Aim. To collect and analyze data on the administration of siponimod in SPMS patients within Russia’s RCP as part of the EMBOSSES study (rEtrospective Multicenter oBservatiOnal Study Siponimod rEal-world Spms).Materials and methods. The study encompassed data of 606 SPMS patients from 11 centers who received siponimod for at least 6 months. The analysed data included demographic and clinical characteristics of patients, changes in the Expanded Disability Status Scale (EDSS) scores over time, percentage of patients with 6-month confirmed disability progression (6mCDP), annualized relapse rate (ARR) for MS, radiological signs of the disease activity and adverse events (AEs).Results. Among the study patients, women predominated (64.9%), while men accounted for 35.1%. The median age of patients was 49.5 (±8.9) years. 143 (23.6%) patients reported relapses during 2 years, whereas relapse-free SPMS was observed in 463 (76.4%) patients. The average EDSS scores remained stable, demonstrating minimal changes from 5.44 (±0.998) to 5.58 (±1.028) scores during the 2-year therapy. The percentage of patients free from 6mCDP was 85.5%. The KaplanMeier analysis revealed that 25% of patients achieved 6mCDP by Month 27 of therapy. The average ARR decreased from 0.14 to 0.032 at 12 months and remained low (0.062) after 2 years of treatment. The MRI showed a decrease in the percentage of patients with Gd+ T1 lesions to their complete absence over 2 years of therapy. Main AEs: lymphopenia, bradycardia, and elevated liver enzymes; serious AEs were observed in 3.3% of all cases.Conclusions. Siponimod demonstrated efficacy in controlling disability progression and inflammatory activity, as well as a favourable safety profile in patients with SPMS in the RCP setting. The results confirm the feasibility of using siponimod in patients with SPMS.


  • Open Access

    Anti-CD20 therapy and pregnancy planning in multiple sclerosis

    by N. V. Khachanova, V. S. Krasnov, E. P. Evdoshenko, I. V. Zakroyshchikova, D. S. Kasatkin, D. S. Korobko, S. A. Kotiy, P. A. Kuznetsov, E. S. Novikova, E. V. Popova, et al.

    Pregnancy rates are rapidly increasing among women of reproductive age diagnosed with multiple sclerosis (MS). Over the past decades, several studies have proven that MS does not affect the course of pregnancy, and pregnancy does not negatively affect the long-term course of the disease. The results of numerous studies have shown that the frequency of exacerbations in MS patients decreases during pregnancy, but increases after childbirth. According to the summary of product characteristics (SmPC) of disease modifying drugs (DMD) most of them are contraindicated during pregnancy. To prevent possible neonatal risks, it is necessary to use contraception before pregnancy planning for a certain period of time after their last use. Medical data of MS pregnancy registries of patients receiving DMD before, during pregnancy and postpartum provide important information for the formation of further therapeutic approaches. The most valuable are the data from prospective studies with clearly selected points for analysis, including both pregnancy outcomes and newborns health. In the group of anti-CD20 drugs, ocrelizumab has the largest database of use during pregnancy. In February 2025, an expert Advisory Council (AC) was held to review and analyze data on the use of anti-CD20 therapy in family planning. According to AC expert’s opinion the use of ocrelizumab 4.5 months before the planned pregnancy does not have an increased risk of adverse neonatal outcomes and allows effectively to control disease activity during pregnancy and in the postpartum period.

  • Open Access

    Neuromyelitis optica spectrum disorders, terminology and therapeutic issues: amended consensus opinion

    by V. S. Krasnov, Yu. V. Vlasov, E. P. Evdoshenko, D. S. Korobko, M. D. Matson, A. I. Nilov, A. A. Sokolova, N. A. Totolian, N. V Khachanova, M. V. Shumilina, et al.

    In Russian Federation in 2022, the Expert Council adopted the main definitions and terms for neuromyelitis optica spectrum disorders (NMOSD) and proposed a treatment algorithm for patients with NMOSD with antibodies to aquaporin-4 (AQP4-IgG). The publication is intended to present the results of the work of the Russian Expert Council in September 2024. The experts agreed on clarifications of previously published terminology, new definitions, current issues in the therapy of NMOSD, proposed profiles of patients with NMOSD for ravulizumab and a monitoring plan during treatment with this drug, and agreed on an updated algorithm for prescribing medications that prevent exacerbations in patients with NMOSD with AQP4-IgG aged 18 years and older.


  • Open Access

    Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion

    by E. V. Popova, М. В. Аброськина, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaia, E. P. Evdoshenko, D. S. Korobko, A. I. Nilov, M. V. Sutormin, Yu. V. Trinitatskiy, et al.

    In March 2020, oral cladribine was licensed in Russian Federation for the treatment of adult patients with highly active relapsing multiple sclerosis as defined by clinical or imaging features. Three years after the introduction into the Russian market, practical aspects in the use of cladribine tablets we evaluated, including data from real-world studies and the experience gained in the own routine clinical practice. Early initiation of cladribine therapy, use of cladribine in treatment naïve patients and patients with suboptimal response to previous disease-modifying therapy, use of cladribine as the treatment of choice in patients with suboptimal response to platform disease-modifying therapy and washout period while switching to cladribine from other disease-modifying therapy. During the discussion thirteen neurologists from federal and regional centers experienced in multiple sclerosis diagnosis and therapy were asked to answer several questions regarding the practical use of cladribine tables and come to consensus opinion. Consent was reached if at least 75% of the experts agreed on a particular statement. The experts agreed on the possibility to switch patients to cladribine from platform disease-modifying therapy in case of MRI activity or neutralizing antibodies in the absence of relapses activity to achieve better disease control, potential cladribine effects on progression independent of relapses, washout period reduction while switching from natalizumab to cladribine. Consensus opinion will help to manage practical questions regarding cladribine usage.


  • Validation of e-version of Russian-language expanded disability status scale (EDSS) for patients with multiple sclerosis in the Russian Federation

    by A.D. Stepanova, E.P. Evdoshenko, M.V. Shumilina, D.S. Korobko, M.A. Barabanova, M.V. Abroskina, A.F. Vasilenko, Yu.N. Yurchenko, M.V. Davydovskaya

    Objective. To assess the validity and reproducibility of e-version of the expanded disability status scale (eEDSS) compared to original paper form in English and paper form of the validated Russian-language EDSS. Material and methods. The study was conducted in 6 centers of the Russian Federation and approved by the ethics committee. Two raters examined 90 patients meeting the inclusion criteria at two visits. Neurological status was assessed by using of eEDSS, Russian-language e-version and paper from of this questionnaire in each group of 30 patients. Time for filling of each scale was also assessed. The Russian-language e-version of EDSS was represented by web application with built-in decision tree (HTML and JavaScript programming languages). Statistical analysis and visualization of data were carried out using the R 4.2.2 environment (R Foundation for Statistical Computing, Austria). Results. The Russian-language e-version of EDSS has high rates of intra- and inter-rater reliability and internal consistency. In addition to similar intra-rater reliability for components of the scales between all these scales, the Russian-language e-version of EDSS has higher inter-rater reliability for Visual, Pyramidal, Sensory, Pelvic functional systems (FS), Ambulatory and final score (ICC>0.9). Internal consistency of this scale was sufficient (Cronbach’s alpha >0.7). There was no significant difference in time for filling of each scale: 196 s (159.5—248.5) for Russian-language e-version, 181 s (159.5—204.5) for EDSS, 200 s (167—289) s for paper form of Russian-language EDSS). Conclusion. E-version of the expanded disability status scale (eEDSS) has been created and validated for the first time in the Russian Federation. This scale is the most effective and valid for assessing the neurological status, as well as preferable for routine clinical practice and studies.

  • Validation of Russian-language version of the Expanded Disability Status Scale (EDSS) for patients with multiple sclerosis in the Russian Federation

    by A.D. Stepanova, E.P. Evdoshenko, M.V. Shumilina, D.S. Korobko, M.A. Barabanova, M.V. Abroskina, A.F. Vasilenko, Yu.N. Yurchenko, M.V. Davydovskaya

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить валидность и воспроизводимость русскоязычной версии шкалы EDSS — расширенной шкалы статуса инвалидизации (РШСИ) — в сравнении с оригинальной бумажной формой EDSS на английском языке. МАТЕРИАЛ И МЕТОДЫ Исследование проведено в 6 центрах Российской Федерации и одобрено Этическим комитетом. Участие приняли 60 взрослых пациентов согласно критериям включения. В ходе двух визитов все пациенты осмотрены 2 рейтерами. Оценка неврологического статуса 30 пациентов осуществлялась с использованием EDSS и 30 — с использованием РШСИ. Оценивалось время, затрачиваемое рейтерами на заполнение бумажных форм для каждой шкалы. Использована версия шкалы, переведенная на русский язык 2 переводчиками независимо друг от друга с последующим обратным переводом на английский язык. РЕЗУЛЬТАТЫ Шкалы РШСИ и EDSS обладают сопоставимыми показателями внутриэкспертной и межэкспертной надежности и внутренней согласованности. Обе шкалы показали высокую внутриэкспертную надежность как для функциональных шкал, так и для итоговой оценки в баллах (ICC=0,962 [95% ДИ: 0,937; 0,977] и 0,997 [95% ДИ: 0,994; 0,998] для шкал EDSS и РШСИ соответственно). Межэкспертная надежность в рамках одного визита была выше для РШСИ и оценена как высокая (ICC >0,9) для итоговой оценки в баллах и для отдельных функциональных систем. Внутренняя согласованность шкал оценена как достаточная (альфа Кронбаха=0,78 [95% ДИ: 0,72; 0,82] и 0,74 [95% ДИ: 0,68; 0,79] для шкал EDSS и РШСИ соответственно). Статистически значимая разница времени заполнения шкал EDSS и РШСИ не выявлена: Me (Q25—Q75) 181 (159,5—204,5) с для EDSS; 200 (167—289) с для РШСИ (p=0,6282). ЗАКЛЮЧЕНИЕ РШСИ является надежным и валидным эквивалентом шкалы EDSS и может быть использована в рутинной клинической практике и клинических исследованиях.